Introduction {#s0001}
============

Cigarette smoking is a major risk factor for many adverse health conditions, including vascular disease, respiratory disease and lung cancer (IARC, [@CIT0017]; Stratton, et al., [@CIT0034]). Given this, the tobacco industry has spent many years investigating reduced exposure technologies, cigarettes and devices, which ultimately may limit exposure in those that continue to smoke tobacco products. The concept of tobacco harm reduction is defined by the Institute of Medicine (IOM) as "decreasing total morbidity and mortality without completely eliminating tobacco and nicotine use" (Institute of Medicine, [@CIT0020]), through the use of potentially reduced exposure products (Stratton et al*.*, [@CIT0034]). The use of such products may reduce the risk of one or more specific diseases or other adverse health effects compared with the risks associated with the use of traditional tobacco products (Institute of Medicine, [@CIT0020]; Stratton et al., [@CIT0034]).

The chemical composition of smoke from any product results from the choice of tobacco blend, the design/format, the presence or absence of a filter and the respective filter components, such as charcoal and/or other selective adsorptive materials. Recent examples of technologies used to reduce toxicant profiles include, but are not limited to; substitute tobacco sheet, which acts as a tobacco diluent (McAdam et al., [@CIT0027]); the development and refinement of cigarette design, format and selective filtration (Bombick et al., [@CIT0006]; Branton et al., [@CIT0007],[@CIT0008]; Dittrich et al., [@CIT0011]; Norman, [@CIT0028]); treatment of tobacco prior to cigarette manufacturing (Liu et al., [@CIT0025]); agronomic practices (Lewis et al., [@CIT0024]) and the development of alternative products such as electronic cigarettes and heat not burn devices (Doolittle et al., [@CIT0012]; Goniewicz et al., [@CIT0015]; Smith et al., [@CIT0035]).

It has been widely accepted that short term *in vitro* studies may provide valuable information (Andreoli et al., [@CIT0004]) on the toxicity of cigarette smoke and may even be useful to measure the mechanistic and biological end-points linked to chronic disease states, biomarkers of disease or biological effect. *In vitro* genotoxicity and cytotoxicity tests are used world-wide for new chemicals as an initial screen to determine their mutagenic and cytotoxic potential. International guidelines have also been developed (e.g. Organization for Economic Cooperation and Development; International Conference on Harmonization \[ICH\]) to ensure uniformity of testing procedures prior to submission of data to regulatory agencies. Currently, no such guidelines exist for the testing of smoke aerosols derived from tobacco products *in vitro*. This limits the capability of the tobacco industry and others involved in tobacco-related research to assess and compare current products with potentially reduced exposure products and other tobacco aerosols such as electronic cigarettes and products that heat tobacco as opposed to burning it. As a result there is a clear need and drive to develop *in vitro* approaches for aerosol testing.

The efficiency with which *in vitro* assays can be conducted and the relevance of the results depends solely on the test article. In the context of human risk to smoking and smoke related products, the test article (smoke aerosol) should mimic as close as possible, human exposure. With the advent of aerosol air--liquid interface (ALI) exposure devices and technologies, such as those supplied by CULTEX®, Vitrocell®, Borgwaldt, Burghart and even one off bespoke systems (Thorne & Adamson, [@CIT0036]), there is focus on optimizing existing *in vitro* techniques and to develop new ones to work alongside these aerosol-exposure devices. With the development of these new exposure technologies comes a necessity to understand aerosol dilution, delivery and exposure principles, which may differ between smoke exposure technologies. This will ultimately ensure that any conclusions derived from data are accurate and appropriately considered and will facilitate cross-platform comparisons.

This study describes the evaluation of a Mouse fibroblast (BALB/c 3T3 clone A31) cytotoxicity technique to discriminate between cigarette smoke aerosols *in vitro* using reference and specially designed products, aimed at the modification of the vapor phase, whilst balancing particulate and puffing parameters. The applicability and functionality of this protocol was confirmed with the use of reference cigarettes, 1R5F, 3R4F and the CORESTA Monitor (CM7), all delivering different smoke toxicant yields. Biological responses from 3R4F reference cigarette smoke, generated 12 months apart were directly compared, for assay variability and robustness and found to be statistically comparable. A more structured approach was also investigated, where different experimental cigarettes were manufactured, matched for variables such as particulate and nicotine delivery, puff number, pressure drop (PD), carbon monoxide (CO), ventilation and blend, but significantly modified for vapor phase delivery through the incorporation of two different adsorptive carbons. This strategy allows cigarettes to be directly compared with each other in a consistent manner, whilst investigating vapor phase-only associated effects. The vapor phase is made up of known smoke toxicants (Fowles & Dybing, [@CIT0013]; Hoffmann et al., [@CIT0016]), with clear biological activity, it is also theorized to be the driving contributor of cytotoxicity. This is supported by extensive *in vitro* and *in vivo* data all showing the cytotoxicity and mutagenicity of the vapor phase of cigarette smoke, indicating this as a significant driver of potential adverse health effects (Azzopardi et al., [@CIT0005]; Bombick et al., [@CIT0006]; Fukano et al., [@CIT0014]; Witschi et al., [@CIT0043]).

This study demonstrates clear differences between these manufactured products and their associated dilution IC~50~ (defined as the dilution at which 50% cytotoxicity is observed). It concludes that this *in vitro* test combined with an aerosol exposure device such as the Vitrocell® VC 10 can be further used to assess the potential cytotoxicity of future aerosol related tobacco products, which may be especially beneficial when comparing aerosols generated from potentially reduced exposure products and alternative and emerging tobacco categories, particularly those aimed at the reduction of vapor phase components of the smoke which are not easily captured or assessed *in vitro*.

Materials and methods {#s0002}
=====================

Chemicals and reagents {#s0003}
----------------------

All chemicals and reagents were obtained from Sigma-Aldrich (Gillingham, UK) unless otherwise stated. All cell culture media was obtained from Gibco® via Life Technologies (Paisley, UK).

Cigarettes {#s0004}
----------

Kentucky reference cigarettes, 1R5F and 3R4F were obtained from the University of Kentucky (Kentucky, USA), CM7 was supplied by Cerulean, UK. All other cigarettes used in this study were manufactured at British American Tobacco's Research and Development facility (Southampton, UK). Prior to analysis, all cigarettes were conditioned for at least 48 h at 22 ± 1°C and 60 ± 3 % relative humidity in accordance with the International Organization of Standardisation (ISO) guideline (ISO 3402:[@CIT0021]). Cigarettes were smoked exclusively to the ISO puff regime, defined as one 35 ml puff per 60 s, over 2 s (ISO 3308:[@CIT0022]) with an 8-s exhaust.

Manufactured cigarettes were made to the same specification \[length, circumference, blend, ventilation, filter configuration, PD (often referred to as the draw resistance of a cigarette)\], but modified for filter additive, using either activated coconut charcoal (CC) or activated synthetic carbon (SC). Cigarettes were manufactured with a dual filter with different quantities of either CC or SC (45, 80, 80 or 110 mg SC). A control product was manufactured to the same technical specification with a mono cellulose acetate (CA) filter, termed Control.

Test cigarettes were constructed to a cigarette circumference of 24.6 mm with a 56 mm tobacco rod containing 43% Virginia, 25% Burley, 9% oriental tobacco blend, with 10% stem, 5% extruded and 8% reconstituted tobacco. Cigarettes were manufactured to a tobacco rod density of 240 mg/cm^3^ with a moisture content of 13.5%, with a 27 mm filter segment (either a mono acetate or a dual filter carbon segment) to a total cigarette length of 83 mm. The only marked difference in these cigarettes was the filter additive. Carbon particles were interspersed amongst the CA set in a commercially based dual filter configuration next to the tobacco rod, with 7% triacetin plasticizer ([Figure 1](#F0001){ref-type="fig"}). Figure 1.Schematic design and specification of the manufactured test cigarettes. CC, coconut carbon; SC, synthetic carbon.

The amount of and type of carbon added to test cigarette filters was selected to produce a range of different vapor phase yield products. Irrespective of carbon type and loading, cigarettes were matched for key characteristics such as, nicotine free dry particulate matter (NFDPM) delivery (mg/cig), open cigarette PD, CO (mg/cig), puff number (/cig), ventilation (%) and nicotine (mg/cig), to create a balanced comparable study ([Table 1](#t0001){ref-type="table"}). Table 1Product specification and parameter breakdown for manufactured cigarettes.Cigarette codeControl45 mg CC80 mg CC80 mg SC110 mg SCFilter type and additiveMono CADual CA/CarbonDual CA/CarbonDual CA/CarbonDual CA/CarbonCarbon typeN/ACoconutCoconutSyntheticSyntheticCarbon weight (mg)N/A478181106Filter length (mm)2727272727Filter PD (mm WG)7577757371Filter ventilation (%)4346454544Carbon segment length (mm)N/A11.812.112.111.6Open cigarette PD (mm WG)83.884.183.180.985.3Tobacco rod length (mm)56.156.356.055.756.3Tobacco density (mg/cm^3^)244.6248.1256.4254.2258.3Tobacco weight (mg)657.8693.1688.1672.3687.4Paper porosity (CORESTA units)44.442.944.744.145.2[^1]

The use of activated carbons in cigarette filters has been widely established. This is due to the relative ease in which coconut shell-derived carbon can be manufactured, and the understanding of increased cigarette filtration and adsorption efficiencies (Branton et al., [@CIT0008]; Coggins & Gaworski, [@CIT0010]; Tokida et al., [@CIT0040]). Activated coconut carbon was obtained from Jacobi carbons Ltd, UK. Generation of carbon activity was achieved by charring raw coconut shell at ∼300--500 °C and then activating it in a rotary kiln at 900--950 °C using steam, prior to crushing and grinding. Synthetic polymer-derived carbon was produced in batches (Branton et al., [@CIT0008]; Von Blücher et al., [@CIT0042]). Polymer feed-stock was thermally stabilized using oleum, and heated to 500 °C resulting in carbonization of the polymer material. An activated porous system was created in the carbon by heating the material to 900--1000 °C ([Table 2](#t0002){ref-type="table"}). Table 2.Characteristics of coconut-shell compared with synthetic derived carbon. Carbon typeCharacteristicsCoconut shell-derivedPolymer/synthetic-derivedAbbreviationCCSCCarbon shapeIrregularSphericalCarbon size distribution0.2--0.60 mm0.25--0.58 mmActivated carbon precursor. Activation mediaCoconut shell derived. Steam activated to 300--950 °C, crushed and ground to sizeSynthetic polymer derived. Feed-stock prepared, stabilized, heated to 500 °C and activated using steam and CO~2~Pore size volumePredominantly microporousBimodal pore size distribution Micropore volume 0.40 cm^3^/gMicropore volume 0.76 cm^3^/g Total pore volume 0.42 cm^3^/gTotal pore volume 1.22 cm^3^/gSurface area (m^2^/g)9801780Density (cm^3^/g)0.460.40

Chemical analysis {#s0005}
-----------------

Chemical analyses were conducted by Labstat International, ULC. Chemicals were selected for measurement due to their status as proposed toxicants by the World Health Organization for mandatory lowering in cigarette smoke (Burns et al., [@CIT0009]). Five independent analyses were conducted per analyte. A brief account of the techniques employed is described in the Supplementary Data. For a more detailed account of the techniques please refer to Wright ([@CIT0044]).

Cell culture {#s0006}
------------

Mouse fibroblasts (BALB/c 3T3 clone A31) were obtained from the European Collection of Cell Cultures. BALB/c 3T3 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM; containing 4 mM glutamine and 4.5 g/l glucose supplemented with 10% foetal calf serum and penicillin/streptomycin) at 37 ± 1 °C in an atmosphere of 5.0% CO~2~ in air. For whole smoke exposure, monolayer cultures were prepared on permeable membranes (24 mm Transwells®, Fisher Scientific, UK) by seeding 5 × 10^5^ cells in 1 ml DMEM into each Transwell® (pre-equilibrated by soaking in DMEM for at least 1 h). Cells were incubated for ∼24 h at 37 °C in a humidified atmosphere of 5% CO~2~ in air to achieve ∼90% confluent monolayers.

Smoke generation and exposure {#s0007}
-----------------------------

A Vitrocell® VC 10 Smoking Robot (Vitrocell® Systems, Waldkirch, Germany), serial number VC10/090610 was used to generate, dilute and deliver cigarette smoke to BALB/c 3T3 cells housed in 6/4 CF stainless steel exposure modules and maintained at the ALI at 37 °C. The VC 10 is a rotary style smoking machine that has a single syringe which transfers the tobacco smoke to an independent continuous flow dilution bar. Different smoke concentrations are achieved by increasing or decreasing the diluting airflow (l/min). In this system increasing airflow, decreases the available smoke concentration and vice-versa. A vacuum sub-samples smoke (via negative pressure) from the dilution bar into the module, which docks directly under the dilution system. Vacuum flow rate was maintained at 5.0 ml/min/well for all treatments. Diluting airflow rates within this system were controlled using mass flow controllers and vacuum rates were set by mass flow meters (Analyt-MTC GmbH, Mülheim, Germany) ([Figure 2](#F0002){ref-type="fig"}). Figure 2.A schematic representation of the Vitrocell® VC 10 smoke exposure system. **(A)** Computer, software controller and air-flow controller. **(B)** Smoking Robot carousel and ventilation hood where cigarettes are smoked. **(C)** Piston/syringe which draws and delivers smoke to the dilution system. **(D)** Dilution, transit and delivery of aerosol occurs in the dilution bar. **(E)** Smoke exposure module (Vitrocell® 6/4 CF Stainless Steel module) which holds the Transwells® maintained at the ALI. Smoke is sampled from the dilution system into the exposure module via negative pressure applied through a vacuum pump at 5 ml/min/well. The central islands can be removed and QCMs can be installed into each position or as shown in position 4 \[Taken from Thorne et al. ([@CIT0036]).\].

For each experiment, triplicate Transwells® were housed in a Vitrocell® 6/4 CF stainless steel module. Trumpet heights within the module were set at 2 mm above the Transwell® membrane. BALB/c 3T3 cells were exposed for 3 h on three independent occasions at the ALI to varied concentrations (eight doses) of either whole smoke or gas vapor phase (GVP). The GVP was generated by capturing the particulate material on a Cambridge filter pad (CFP) positioned between the smoking head and syringe.

Neutral red uptake cytotoxicity test {#s0008}
------------------------------------

The neutral red uptake assay was performed as previously described by Thorne et al. ([@CIT0038]) and is based on the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) BALB/c 3T3 test method, with modifications for aerosol ALI exposure. Briefly, cells were incubated in DMEM culture media containing 50 µg/ml Neutral Red for 3 h. Neutral Red dye was released by the addition of Neutral Red de-stain solution \[ethanol: acetic acid: distilled water; (50:1:49)\] and was measured by absorbance at 540 nm. For each condition a dilution IC~50~ was calculated on a l/min diluting airflow rate (defined as a smoke dilution at which 50% cytotoxicity is achieved). A concurrent air control, included in each exposure, which provided a base-line normalization factor on which analysis was conducted. Experiments were deemed valid if they met the following acceptance criteria; OD~50~ coefficient of variance values were \<15%; positive control treatments caused \>50% decrease in viability relative to the air control, and the air control cell survival was ≥70%.

Quartz crystal microbalances {#s0009}
----------------------------

Quartz crystal microbalances (QCMs) were used in this study to assess smoke deposition (µg/cm^2^) *in situ.* QCM technology has been previously described in conjunction with *in vitro* whole smoke exposure systems (Adamson et al., [@CIT0002], [@CIT0003]; Majeed et al., [@CIT0026]; Thorne et al., [@CIT0037]). In this study a QCM was installed into position 4 (furthest position within the module) and recorded mass values every 2 s in a real-time format.

Data presentation and statistics {#s0010}
--------------------------------

GraphPad Prism 6 (2012) statistical software, version 6.0 was used to generate a dilution IC~50~ and to assess the curve using regression analysis. Best fits were generated using a sigmoidal four-parameter-logistic curve for all data with statistical analysis. Statistical analysis was conducted using GraphPad Prism and/or in Minitab® version 16.1.0 with a two-sample one-way analysis of variance, using Dunnett's test. All assessments were conducted on three independent occasions/cigarette, with three replicates/dose/occasion and assessed to a 95% confidence limit.

Results {#s0011}
=======

Smoke chemical analysis was conducted on all cigarettes assessed in this study. [Tables 3](#t0003){ref-type="table"} and [4](#t0004){ref-type="table"} show a detailed break-down of the smoke chemistries for the reference cigarettes and manufactured cigarettes, respectively. Mainstream cigarette smoke chemistry data obtained for 3R4F in this study are consistent with that previously published in (Roemer et al., [@CIT0031]). Table 3.Smoke analyte yields for reference cigarettes, measured under ISO smoking conditions.   Yields (±SD)GroupAnalytesUnits1R5F3R4F^a^CM7Ammonia μg/cig2.5 (0.5)10.3 (0.2)19.3 (0.9)Aromatic amines1-aminonaphthaleneng/cig3.9 (0.1)15.1 (0.9)24.2 (1.3) 2-aminonaphthaleneng/cig2.7 (0.1)9.8 (0.5)13.7 (1.1) 3-aminobiphenylng/cig0.7 (0.0)1.9 (0.1)2.4 (0.2) 4-aminobiphenylng/cig0.6 (0.0)1.4 (0.0)1.6 (0.2)Benzo\[a\]pyrene ng/cig1.3 (0.2)6.3 (0.3)14.9 (1.0)CarbonylsFormaldehydeμg/cig3.8 (0.4)22.8 (1.7)43.4 (1.3) Acetaldehydeμg/cig115.9 (9.8)447.5 (16.5)564.7 (27.1) Acetoneμg/cig69.7 (4.8)238.2 (8.2)283.6 (15.7) Acroleinμg/cig10.2 (0.7)51.5 (0.8)68.5 (3.3) Propionaldehydeμg/cig11.6 (1.2)42.1 (2.1)51.5 (3.1) Crotonaldehydeμg/cigNQ11.5 (0.7)20.6 (0.8) MEKμg/cig20.4 (1.9)65.8 (3.2)76.6 (5.7) Butyraldehydeμg/cig9.7 (0.9)29.3 (1.7)42.4 (3.2)HCN μg/cig16.6 (0.9)88.5 (4.0)148.7 (7.8)Nitric oxidesNOμg/cig90.2 (8.9)204.5 (8.9)88.0 (4.2) NOxμg/cig96.9 (9.7)219.1 (9.6)95.3 (4.9)Tobacco-specific nitrosaminesNitrosonornicotine (NNN)ng/cig44.9 (2.1)98.8 (2.2)17.6 (1.2) Nitrosoanatabine (NAT)ng/cig43.6 (2.5)106.7 (2.5)34.2 (2.5) Nitrosoanabasine (NAB)ng/cig7.9 (0.7)14.0 (0.1)4.9 (0.4) 4-(N-nitrosomethylamino)-1-(3-pyridyl)- 1-butanone (NNK)ng/cig23.7 (2.0)85.7 (2.9)21.7 (1.7)Nitrogen heterocyclicsPyridineμg/cig1.9 (0.1)7.1 (0.2)13.0 (0.3) Quinolineμg/cig0.0 (0.0)0.2 (0.0)0.5 (0.0) Styreneμg/cig1.9 (0.1)5.7 (0.4)10.6 (0.5)Phenolic compoundsHydroquinoneμg/cig7.5 (0.3)33.1 (2.1)93.3 (5.1) Catecholμg/cigNQ35.2 (2.0)94.4 (4.4) Phenolμg/cigNQ9.9 (0.9)35.8 (2.2) m-cresolμg/cigNQ1.8 (0.1)4.0 (0.2) p-cresolμg/cig0.8 (0.1)5.7 (0.3)14.0 (0.8) o-cresolμg/cigBDL2.4 (0.2)5.0 (0.2) Resorcinolμg/cigBDLNQNQVolatiles1,3-butadieneμg/cig12.1 (0.6)34.9 (0.9)51.0 (2.6) Isopreneμg/cig113.3 (4.5)306.7 (12.2)413.5 (20.8) Acrylonitrileμg/cig1.8 (0.1)6.7 (0.5)10.7 (0.7) Benzeneμg/cig11.5 (0.4)31.6 (2.0)42.4 (1.8) Tolueneμg/cig18.4 (1.2)56.6 (4.6)73.9 (3.5)ISO smoke yieldsNFDPMmg/cig1.7 (0.2)8.1 (0.4)13.4 (0.6) Nicotinemg/cig0.1 (0.0)0.7 (0.0)1.2 (0.1) COmg/cig2.5 (0.4)10.5 (0.3)11.3 (1.1) Puff number/Cig6.5 (0.2)8.0 (0.2)8.1 (0.3)[^2] Table 4.Smoke analyte yields for bespoke manufactured cigarettes, measured under ISO smoking conditions.   Yields (±SD)GroupAnalytesUnitsControl45 mg CC80 mg CC80 mg SC110 mg SCAmmonia μg/cig8.6 (0.6)8.3 (0.5)8.4 (0.6)8.4 (0.5)9.0 (0.2)Aromatic amines1-aminonaphthaleneng/cig14.0 (1.0)15.5 (1.4)14.3 (0.6)19.5 (2.3)20.1 (1.1 2-aminonaphthaleneng/cig9.4 (0.7)10.2 (0.9)10.3 (0.6)11.8 (0.7)12.4 (0.9) 3-aminobiphenylng/cig1.9 (0.1)2.2 (0.2)2.2 (0.1)2.4 (0.1)2.6 (0.1) 4-aminobiphenylng/cig1.5 (0.1)1.6 (0.1)1.7 (0.1)1.9 (0.1)2.0 (0.1)Benzo\[a\]pyrene ng/cig6.2 (0.9)6.3 (0.5)6.4 (0.5)6.5 (0.7)7.2 (0.7)CarbonylsFormaldehydeμg/cig17.8 (1.8)15.1 (1.1)14.2 (2.0)13.8 (1.4)12.8 (0.7) Acetaldehydeμg/cig416.0 (11.4)347.9 (24.8)244.8 (24.1)72.2 (9.0)29.2 (10.9) Acetoneμg/cig180.9 (5.1)136.6 (12.4)68.4 (7.6)6.2 (0.8)4.1 (0.7) Acroleinμg/cig32.6 (2.2)22.8 (3.4)10.6 (1.6)2.8 (0.3)NQ Propionaldehydeμg/cig32.4 (1.3)24.1(2.0)13.5 (1.5)NQBDL Crotonaldehydeμg/cig7.7 (0.7)NQNQBDLBDL MEKμg/cig44.3 (1.3)28.2 (3.6)11.3 (1.7)NQNQ Butyraldehydeμg/cig25.0 (1.2)18.5 (1.7)12.0 (0.8)3.4 (0.1)NQHCN μg/cig83.3 (3.8)61.7 (4.8)35.1 (2.0)22.7 (2.4)15.6 (2.0)Nitric oxidesNOµg/cig115.4 (11.0)134.7 (6.7)128.0 (5.9)122.1 (10.8)114.0 (9.3) NOxµg/cig125.2 (11.5)144.6 (7.0)136.8 (6.6)127.5 (11.0)119.2 (9.2)Tobacco-specific nitrosaminesNNNng/cig84.9 (5.7)94.4 (4.3)97.4 (4.0)107.8 (8.6)115.4 (10.4) NATng/cig53.8 (4.2)61.0 (1.2)62.3 (3.9)68.4 (4.7)72.8 (2.8) NABng/cig7.8 (0.8)9.2 (0.4)9.1 (1.0)10.6 (1.0)10.9 (1.0) NNKng/cig27.6 (1.9)31.6 (2.6)33.1 (1.6)34.9 (1.2)38.0 (3.1)Nitrogen heterocyclicsPyridineμg/cig6.6 (0.2)2.4 (0.2)1.2 (0.2)NQNQ Quinolineμg/cig0.3 (0.0)0.2 (0.0)0.2 (0.0)0.2 (0.0)0.2 (0.0) Styreneμg/cig4.3 (0.2)1.6 (0.2)0.9 (0.1)NQNQPhenolic compoundsHydroquinoneμg/cig36.0 (2.1)37.4 (1.3)39.2 (1.0)40.8 (1.7)45.0 (1.4) Catecholμg/cig42.8 (2.9)44.6 (2.7)47.8 (0.9)48.5 (1.5)54.1 (2.2) Phenolμg/cig14.2 (1.6)12.9 (1.3)13.2 (0.3)10.1 (0.5)12.2 (0.4) m-cresolμg/cig2.7 (0.2)2.6 (0.2)2.7 (0.0)2.3 (0.1)2.7 (0.1) p-cresolμg/cig6.8 (0.6)6.6 (0.5)6.9 (0.1)5.7 (0.3)6.8 (0.1) o-cresolμg/cig3.5 (0.4)3.1 (0.3)3.1 (0.1)2.4 (0.1)2.8 (0.1) Resorcinolμg/cigNQNQNQNQNQVolatiles1,3-butadieneμg/cig23.2 (2.5)19.0 (1.7)15.6 (1.5)1.1 (0.1)NQ Isopreneμg/cig204.2 (12.6)160.5 (12.4)113.7 (8.4)NQNQ Acrylonitrileμg/cig6.0 (0.6)4.0 (0.2)2.2 (0.4)NQNQ Benzeneμg/cig23.7 (1.7)14.5 (1.2)7.7 (1.0)NQNQ Tolueneμg/cig36.3 (2.9)19.1 (1.5)8.7 (3.4)NQNQISO smoke yieldsNFDPMmg/cig7.5 (0.6)7.4 (0.3)7.9 (0.5)7.6 (0.4)8.3 (0.6) Nicotinemg/cig0.7 (0.0)0.6 (0.0)0.7 (0.0)0.7 (0.0)0.8 (0.1) COmg/cig6.7 (0.5)6.6 (0.3)6.8 (0.6)6.6 (0.3)7.2 (0.7) Puff number/Cig7.2 (0.5)7.5 (0.2)7.6 (0.3)7.7 (0.4)7.7 (0.2)Vapor phase reductions^a^ **%023.451.189.394.6**[^3]

Clear cytotoxicity profiles (defined as a cytotoxic range, from 100 to 0% viability) were generated for all cigarettes tested within this study ([Table 5](#t0005){ref-type="table"}). Table 5.Dilution IC~50~ ranges and curve analysis based on 95% confidence limits.CigaretteDilution IC~50~ (l/min)Dilution IC~50~ range (l/min)*R*^2^ curve fit*p* valueStatistical analysis3R4F--A6.726.25--7.230.900.703\*3R4F--B^a^6.095.27--6.720.890.703\*1R5F1.491.29--1.740.96∼N/ACM78.127.15--9.220.93∼N/AControl5.655.30--6.020.94∼N/AControl + CFP3.643.23--4.110.900.028\*\*45 mg CC4.013.20--5.020.910.316NS45 mg CC + CFP0.800.40--1.580.810.012\*\*80 mg CC3.392.96--3.900.960.002\*\*80 mg SC2.411.93--3.020.940.001\*\* (\*\*\*)110 mg SC1.941.63--2.320.960.009\*\*[^4]

Reference cigarettes {#s0012}
--------------------

The response of 3R4F (3R4F-A) in this study was directly compared and analyzed against previously published 3R4F data (3R4F-B) (Thorne et al., [@CIT0038]). When comparing between the two datasets no statistical difference was observed (*p* = 0.703). 3R4F data generated in this study demonstrated a dilution IC~50~ of 6.70 l/min with a range of 6.25--7.23 l/min and a curve fit of *R* ^2 ^= 0.90. This supports the data published in Thorne et al. ([@CIT0038]), of a dilution IC~50~ of 6.09 l/min. All reference products produced a cytotoxic response. CM7 was deemed the most cytotoxic in this study, followed by 3R4F, with 1R5F producing the lowest cytotoxic response. For the purpose of this study, reference cigarettes were not directly compared, rather these products were used as a 'reference point' to contextualize the study ([Figure 3](#F0003){ref-type="fig"}). Figure 3.Cytotoxicity analysis of reference cigarettes. **(A)** Comparison of 3R4F reference data (3R4F-A) generated in this study compared with historical 3R4F data (3R4F-B) previously published in Thorne et al. ([@CIT0038]). **(B)** Cytotoxic comparison of three different reference cigarettes, CM7. 3R4F and 1R5F.

Manufactured cigarettes {#s0013}
-----------------------

For a more comprehensive and direct comparison, five cigarettes were specially manufactured, matched for key cigarette variables, such as; NFDPM (mg/cig), nicotine (mg/cig), puff number (/cig) PD, ventilation (%) and CO (mg/cig) ([Figure 4](#F0004){ref-type="fig"}). Figure 4.Manufactured cigarettes showing comparable specifications compared with Control.

Manufactured cigarettes were modified with varying filter additives to selectively remove vapor phase chemicals, such as acetaldehyde, acetone, acrolein, benzene, isoprene, hydrogen cyanide (HCN), propionaldehyde and methyl ethyl ketone (MEK) and to produce different vapor phase chemical profiles ([Figure 5](#F0005){ref-type="fig"} and [Table 4](#t0004){ref-type="table"}). Figure 5.A snap-shot of the chemistry profile of 11 vapor phase chemicals for the manufactured cigarettes.

The manufactured cigarette 110 mg SC showed the highest reductions in vapor phase chemistries followed by 80 mg SC, 80 mg CC and finally 45 mg CC, when compared with the Control product. Cigarettes 110, 80 and 80 mg CC, and all showed a statistically lower cytotoxic response compared with the Control. The only cigarette in this study not to show a statistical difference when compared with the Control was 45 mg CC product. Based in order of increasing cytotoxicity the products were ranked as follows, 110 mg SC, 80 mg SC, 80 mg CC and 45 mg CC/Control, with IC~50~ dilutions of 1.94, 2.41, 3.39, 4.01 and 5.65 l/min, respectively. The ranking of the cytotoxicity, mirrors that of the vapor phase profiles in that the higher the chemical reductions the lower the observed cytotoxicity. For example 110 mg SC produced the lowest cytotoxic response, with the highest vapor phase reductions. This trend was observed throughout the five test articles. When the two types of carbon (coconut and synthetic) were directly compared, with matched loading in the cigarette filter, SC was shown to produce a lower cytotoxic response compared with coconut carbon, when matched for weight (80 mg), also following the vapor phase chemical/cytotoxicity reduction trend ([Figure 6](#F0006){ref-type="fig"}). Figure 6.Comparative cytotoxicity analysis of manufactured cigarettes. **(A)** Comparison of all cigarettes tested. **(B)** Comparison of Control versus 45 mg CC. **(C)** Comparison of Control versus 80 mg CC. **(D)** Comparison of Control versus 80 mg SC. **(E)** Comparison of Control versus 110 mg SC and **(F)** Comparison of Control versus 80 mg CC versus 80 mg SC.

Smoke phases {#s0014}
------------

To assess the contribution of the smoke phases, a CFP was installed in-line and particulate material filtered, thus giving a cytotoxic measure of the vapor phase. The 110 mg SC product which gave the highest vapor phase reductions (∼95%) was used to assess the contribution of the particulate phase. No reductions in cell viability were observed in an experiment using a 110 mg SC with a CFP in-line (data not shown), which confirmed that vapor phase chemicals were present below the levels required to elicit a biological response in this assay.

Removal of the particulate phase via a CFP demonstrated a significant reduction in cytotoxicity, from a dilution IC~50~ of 5.65 to 3.64 l/min (Control compared with the Control + CFP). Removal of the vapor phase using 110 mg SC, also demonstrated a significant reduction in cytotoxicity from a 5.65 to 1.94 l/min. The reductions in cytotoxicity were more pronounced when the vapor phase was removed compared with that of the particulate. Based on these observations, it appears that the vapor phase contributes to ∼65% of the cytotoxicity, with the remaining 35% associated with the particulate fraction ([Figure 7](#F0007){ref-type="fig"}). Figure 7.**(A)** Analysis of smoke phase contribution. Whole smoke (Control), vapor (Control + CFP) and particulate (110 mg SC). **(B)** Analysis of smoke phases using carbon filtered products and altered chemistry dynamics.

When a CFP was installed in-line of a 45 mg CC product, it barely produced a full cytotoxic response with a dilution IC~50~ of 0.80 l/min, the lowest cytotoxic response observed in this study. Previous experiments demonstrated that removal of the particulate phase produced an approximate reduction in cytotoxicity of 35%. However, in this instance by removing the particulate fraction from the mainstream smoke of a modified product (45 mg CC), with only mild vapor phase reductions (∼23%), a 80% reduction in cytotoxicity was observed. This result differs from the observed 65:35% vapor/particulate ratio. Although the modified 45 mg CC product was not statistically different from the control in terms of cytotoxicity and had only mild vapor phase reductions, this altered vapor has significantly lower impact without the associated particulate fraction. This potentially indicates a synergistic/additive effect of the smoke fractions.

By comparing responses from particulate and vapor (whole smoke), with particulate only (vapor removed via 110 mg SC), with vapor only (particulate removed via CFP) and in the presence of known vapor phase reductions, the vapor phase biological relationship was identified ([Table 6](#t0006){ref-type="table"}). Table 6.Cigarette smoke phase contributions and proposed vapor phase activity.CigaretteSmoke phase assessedDilution IC~50~ (l/min)^a^% Vapor phase activity^b^% Measured vapor reductions^c^ControlWhole smoke5.651000Control + CFPVapor^d^3.64100045 mg CCVapor reductions and particulate4.016023.480 mg CC 3.394051.180 mg SC 2.411089.3110 mg SCParticulate^e^1.94094.6[^5]

By calculating percentage vapor phase reductions against the Control product ([Table 4](#t0004){ref-type="table"}), and by determining the associated reduction in biological activity ([Table 6](#t0006){ref-type="table"}), the two variables were compared. [Figure 8](#F0008){ref-type="fig"} demonstrates the highlighted relationship between vapor phase reductions and % biological effect (*R* ^2 ^= 0.99), showing that reductions in the vapor phase (and semi-volatile) compounds have a direct and proportional effect on biological activity. Biological activity (%) was measured against the Control product and reduced activity (%) refers to the reduced cytotoxic profiles of the manufactured products when normalized against the Control. Figure 8.Analysis of vapor phase contribution to biological activity. % chemical reductions for vapor and semi-volatiles calculated against Control. % biological activity based on cytotoxic shift, normalized against Control. % biological activity shows a statistical correlation with reductions in vapor and semi-volatile toxicants (*R* ^2 ^= 0.99).

Deposition {#s0015}
----------

Deposited mass values obtained for the reference cigarettes (1R5F, 3R4F and CM7) *in situ* of exposure and were statistically different when compared on a per puff basis (*p* = 0.000). When investigated further, a direct relationship was identified between deposited mass, nicotine and NFPDM for each product (*R* ^2 ^= 0.97 and = 0.96, respectively). When deposited mass values were compared between the five bespoke manufactured products, no statistical differences were observed between products (*p* = 0.147), despite significant toxicant reductions, when compared at a consistent dilution (1 l/min) ([Figure 9](#F0009){ref-type="fig"}). Figure 9.Analysis of deposited mass obtained *in situ* of exposure. **(A)** deposited mass per puff for 1R5F, 3R4F and CM7, showing a statistical difference between products (*p* = 0.000). **(B)** relationship between ng/cm^2^/puff and nicotine/puff (*R* ^2 ^= 0.97). **(C)** relationship between ng/cm^2^/puff and NFDPM/puff (*R* ^2 ^= 0.96). **(D)** deposited mass obtained from the bespoke manufactured cigarettes, showing no statistical differences for deposited mass measured between products (*p* = 0.147), measured at the 1 l/min dilution.

Discussion {#s0016}
==========

This study describes the evaluation of a BALB/c cytotoxicity technique employed alongside a Vitrocell® VC 10 smoke exposure system for the assessment of mainstream cigarette smoke *in vitro*. The BALB/c technique employed is a modification of the ICCVAM acute toxicity test optimized for ALI aerosol exposure. Essentially, this protocol allows for the assessment of semi-volatiles and vapor phase compounds *in vitro*. This is especially important, as tobacco smoke is a complex aerosol consisting of \>6000 chemicals (Rodgman & Perfetti, [@CIT0030]), distributed between both the particulate and vapor phase, with semi-volatiles transiting between phases. Analysis of the particulate material only, omits any interactions or responses generated by the vapor phase. Furthermore, the vapor phase makes up the majority smoke fraction and contains known toxicants responsible for adverse health effects (Fowles & Dybing, [@CIT0013]; Hoffmann et al., [@CIT0016]). Finally, separating smoke fractions may lead to alterations or chemical changes which may not be representative of the complete smoke aerosol. For these reasons, ALI technologies for aerosol exposure *in vitro* are becoming more widely used and adopted.

Eight different cigarettes were assessed, three reference products (1R5F, 3R4F and CM7) and five experimental products. Analysis of cigarette cytotoxic responses using 3R4F reference cigarette smoke demonstrated no statistical difference between data obtained in this study compared with that obtained 12-month prior. This analysis gives confidence in the robustness of the assay, exposure and the biological responses obtained.

For a direct comparative analysis, five experimental products were specifically manufactured and matched for PD, NFDPM yields, Nicotine, Puff number and blend, but significantly altered for vapor phase delivery.through the use of coconut or synthetic carbon (SC). In the context of whole smoke exposure, understanding the contribution of the smoke phases and their interaction is fundamental. In order to obtain a broad spectrum of vapor phase deliveries, two carbons previously described by Branton et al. ([@CIT0008]) and a range of loadings were investigated, all using the same tobacco-blend and cigarette parameters to eliminate potential variability. Clear statistical differences were observed between the cigarette test pieces and the cytotoxic profiles (obtained through a dilution IC~50~) when compared with the Control product. For example, cigarettes 80 mg SC, 80 mg CC and 110 mg SC produced a statistically lower cytotoxic profiles, when compared with the Control. In order of increasing cytotoxicity, the cigarettes are ranked as follows; 110 mg SC, 80 mg SC, 80 mg CC and 45 mg CC/Control, which corresponds directly with the amount of vapor phase toxicants removed per product.

SC has previously been demonstrated to be more efficient at vapor phase removal compared with traditional coconut carbon (Branton et al., [@CIT0008]), and the chemistry data from this study support this. Directly comparing the cytotoxic response between the two different carbon products, demonstrated that matched for loading, SC cigarettes produced a significantly different (*p* = 0.016) and lower cytotoxic response compared with traditional coconut carbon. Although other studies have demonstrated the effect of carbon loadings on cigarette induced cytotoxicity (Bombick et al., [@CIT0006]; Coggins & Gaworski., [@CIT0010]; Phillips et al., [@CIT0029]; Shin et al., [@CIT0032]), none have balanced the tobacco blend, NFDPM yields and puffing characteristics of the particulate phase, whilst demonstrating reductions in the vapor phase yields. By calculating % vapor and semi-volatile toxicant reductions and, by calculating the % cytotoxic shift of each product normalized against the Control, the relationship between cytotoxicity and vapor phase and semi-volatile chemicals was defined. The data show a clear direct and statistical relationship (*R* ^2 ^= 0.99) between vapor phase reductions and reduced biological response. The relationship suggests that reductions in vapor phase toxicants have a direct and proportional impact on the observed biological response in the set-up under these experimental conditions.

Additionally, analyses of the contribution of the particulate and vapor smoke phases towards cytotoxicity were examined. Removal of the particulate phase from the Control product via a CFP produced a significant reduction in cytotoxicity, as did removal of the vapor phase (through 110 mg SC). The reduction in cytotoxicity was more pronounced when the vapor phase was removed compared with that of the particulate fraction. Based on these observations, the vapor phase contributes ∼65%. This differs from previous estimations and puts more emphasis on the vapor phase. For example previous studies have estimated an even split between the particulate and vapor contribution towards cytotoxicity, using a comparable set-up (Thorne et al., [@CIT0038]). The disparity between these observations can be attributed to the fact that previous studies did not consider both the complete removal of the particulate or the vapor phase, as this study has done, thus allowing more accurate interpretations of the data.

In addition to assessing the various smoke phases, a CFP was installed in-line of a 45 mg CC product, which barely produced a full cytotoxic dose response. Previous experiments demonstrated that removal of the particulate phase produced an approximate reduction in cytotoxicity of 35%. By removing the particulate fraction from the mainstream smoke of a modified product (45 mg CC), with only mild vapor phase reductions (∼23%), a 80% reduction in cytotoxicity was observed. This result differs from the observed 65:35% estimated vapor/particulate ratio. This altered vapor phase demonstrated significantly lower impact without the associated particulate fraction, potentially indicating a synergistic/additive effect. This reduced cytotoxic response may be attributed to the change in vapor phase characteristics from the filtered product and the lower levels of interactions in the vapor phase and semi-volatile chemicals present. In addition, by removing the particulate and modifying the vapor phase delivery through a carbon filtered cigarette, the resulting cytotoxic profile can be attributed to chemicals within the complex cigarette smoke mixture, such as formaldehyde, acetaldehyde, crotonaldehyde, acrolein, acetone, propionaldehyde, acrylonitrile and HCN. These chemicals have all previously been associated with lung injury, tissue damage and have distinct modes of action (Fowles & Dybing, [@CIT0013]; IARC [@CIT0017], [@CIT0018], [@CIT0019]).

QCMs were included in this study to assess the deposited material from each product. Due to the nature of the study, in that chemistries were obtained and that cigarettes were balanced for particulate and modified for vapor and semi-volatile deliveries, the QCM data obtained was far more valuable and informative. Based on a per puff delivery (ng/cm^2^) significant differences were observed in the deposited material obtained between the three reference products tested (1R5F, 3R4F, CM7). This is explained as these products differ in both vapor and particulate deliveries and have clear nicotine and NFDPM yield differences. QCM data for the experimental cigarettes showed a contrasting pattern. No statistical differences were observed for deposited material between any of the bespoke products tested when compared with the Control at a set dilution (1 l/min). This data suggest that QCMs are only detecting the particulate fraction of the cigarette smoke and not any deposited vapor or semi-volatiles, as previously hypothesized. Additionally, if QCMs were measuring an element of the semi volatile or vapor phase deposited or adsorbed material, this study would have expected to see a reduction in QCM readings for the modified products, given that the highest vapor phase modified product (110 mg SC), showed ∼95% reduction in vapor and semi volatiles compared with Control; no such reductions were observed in QCM data. QCM readings from the reference products were compared with NFDPM and nicotine chemistries obtained. A clear relationship between deposited mass per puff and NFDPM and Nicotine per puff was identified (*R* ^2 ^= 0.97 and 0.96, respectively).This supports the theory that QCMs are only measuring the particulate phase of cigarette smoke, thus helping us understand their importance and capacity in *in vitro* exposure scenarios.

Conclusions {#s0017}
===========

The data presented here is based on a modified BALB/c protocol and the Vitrocell® VC 10 whole smoke exposure system, which has demonstrated the ability to distinguish between altered vapor phase products and produced consistent and robust responses for 3R4F reference cigarette smoke data generated over 12 months. This study has demonstrated a clear, direct vapor phase cytotoxic effect dose response relationship, derived from mainstream cigarette smoke from bespoke manufactured cigarettes. It has clarified the contribution of the respective smoke phases, vapor and particulate, towards cytotoxicity in ∼65:35% ratio in favor of the vapor phase. In addition the study has potentially highlighted an *in vitro* vapor particulate phase interaction that is altered once cigarette smoke has been filtered. It has also highlighted that key vapor phase chemicals, such as the carbonyls, can drive cytotoxicity without the corresponding particulate fraction of smoke. Finally, the data shown here demonstrates the essential requirement to develop ALI-based techniques for the appropriate analysis of the complete smoke aerosol *in vitro*, which will be of particular and of growing importance as new aerosol based tobacco products become more widely accepted and used.
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[^1]: CA, cellulose acetate.

[^2]: ^a^Values consistent with Roemer et al. ([@CIT0031]).

    BDL, below limit of detection; NQ, not quantifiable.

[^3]: ^a^Reductions based on percentage difference of vapor and semi-volatile chemicals normalized against Control (Calculation based on reductions of carbonyls, HCN, nitrogen hetrocyclics, volatiles, through carbon filtration).

    BDL, below limit of detection; NQ, not quantifiable.

[^4]: ^a^Data taken from Thorne et al. ([@CIT0038]).

    CFP, Cambridge filter pad; N/A, statistical analysis not applied; NS, not statistically different compared with Control.

    \*No statistical difference between 3R4F datasets (A and B) when compared with each other (*p* = 0.703).

    \*\*Statistically lower cytotoxicity when compared with Control.

    \*\*\*Statistically lower cytotoxicity when compared with 80 mg CC (*p* = 0.016).

[^5]: ^a^Obtained dilution IC~50~ response.

    ^b^Percentage biological activity attributed to the vapor phase, normalized against Control.

    ^c^Reductions based on percentage difference of vapor and semi-volatile chemicals in each product normalized against Control.

    ^d^Particulate phase filtered using CFP.

    ^e^Vapor phase filtered using performance carbon.
